FACS assay shows that recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.01 μg/mL (Routinely tested).
Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| MEDI-6469 | MEDI-6469 | Phase 2 Clinical | Providence Cancer Center, Agonox | Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma | Details |
| Vonlerolizumab | RG-7888; MOXR-0916; RO-7021608 | Phase 1 Clinical | Genentech Inc | Carcinoma, Transitional Cell; Neoplasms | Details |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasms; Neoplasm Metastasis | Details |
| KHK-4083 | KHK-4083 | Phase 2 Clinical | Kyowa Hakko Kirin Co Ltd | Abdominal Pain; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases | Details |
| ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience | Neoplasms | Details |
| GBR-830 | GBR-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Dermatitis, Atopic | Details |
| INCAGN-1949 | INCAGN-1949 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Carcinoma, Renal Cell; Urogenital Neoplasms; Neoplasm Metastasis | Details |
| Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) | YH-002 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours | Details |
| PF-04518600 | PF-8600; PF-04518600 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Carcinoma, Renal Cell; Neoplasms; Lymphoma, Follicular; Breast Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell | Details |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Neoplasms | Details | |
| GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Neoplasms; Multiple Myeloma | Details |
| mRNA-2416 | mRNA-2416; OX40L mRNA - Moderna Therpeutics | Phase 2 Clinical | Moderna Therapeutics | Ovarian Neoplasms; Solid tumours; Lymphoma | Details |
| Cudarolimab | IBI-101 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| BAT-6026 | BAT-6026 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd, Bio-Thera Solutions Ltd | Solid tumours | Details |
| BGB-A445 | BGB-A445 | Phase 1 Clinical | Beigene Ltd | Solid tumours | Details |
| BMS-986178 | BMS-986178 | Phase 2 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| INBRX-106 | INBRX-106; ES-102; ES102 | Phase 1 Clinical | Inhibrx | Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
